The US Food and Drug Administration (FDA) has approved an oral contraceptive (Safyral; Bayer Healthcare Pharmaceuticals, Inc) in which 451 μg levomefolate calcium has been added to each tablet of a 21/7 drospirenone 3 mg/estradiol 30 μg regimen. Adverse events associated with use of folate-boosted oral contraceptives most commonly include premenstrual syndrome (12.4%), headache/migraine (10.3%), [...]



